ArticleFrontiers in cardiovascular medicine2026
Association between serum ANGPLT8 levels and atherogenic index of plasma in Chinese patients with type 2 diabetes mellitus.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Angiopoietin-like protein 8 (ANGPTL8), a secreted adipokine, has been reported to be associated with lipid and glucose metabolism. This study aimed to evaluate the association between circulating levels of ANGPTL8 and atherogenic risk, assessed by the atherogenic index of plasma (AIP), in diabetic individuals. Methods: A total of 228 patients with type 2 diabetes (T2D) were included in this cross-sectional study. The AIP was calculated as the logarithm of the ratio of triglycerides (TG) to high-density lipoprotein cholesterol (HDL-c) and divided into two subgroups of low and high risk of CVD, as <0.11 and ≥0.11, respectively. Data including clinical characteristics and laboratory tests were collected. Serum levels of ANGPTL8 were assessed by ELISA analysis. Results: Serum concentrations of ANGPTL8 were significantly higher in the high AIP group compared with the low AIP group [293.84 (255.63-332.05) ng/mL vs. 223.05 (202.85-243.25) ng/mL; Conclusions: The serum ANGPTL8 levels are elevated in T2D patients with high AIP. Increased ANGPTL8 levels are closely associated with higher AIP values, indicating a predictive value of ANGPTL8 in atherosclerosis in patients with T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.